Department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections
The WHO Department leads the global effort to end the epidemics of HIV, tuberculosis (TB), hepatitis, and sexually transmitted infections (STIs), ensuring that every person has equitable access to highest-quality people-centred scientific evidence and services, regardless of who they are or where they live.
Types of drug-resistant TB
Mono-resistance: resistance to one first-line anti-TB drug only
Poly-resistance: resistance to more than one first-line anti-TB drug, other than both isoniazid and rifampicin
Multidrug resistance (MDR): resistance to at least both isoniazid and rifampicin
Extensive drug resistance (XDR): resistance to any fluoroquinolone, and at least one of three second-line injectable drugs (capreomycin, kanamycin and amikacin), in addition to multidrug resistance
Rifampicin resistance (RR): resistance to rifampicin detected using phenotypic or genotypic methods, with or without resistance to other anti-TB drugs. It includes any resistance to rifampicin, in the form of mono-resistance, poly-resistance, MDR or XDR.